Ann: 2018 AGM Presentation, page-21

Billy, sorry for the slow reply. Of course you are right. This has become the bad news company for sure over the last 5 years. Theoretically it is still poised for a P3 in HD if they could get a regulator to OK that trial. If they were even trying. My positive outlook is based on what the prospects are from here in the present, with PBT434, at this price. 

A US based development team has taken over, and they have a very good record. So far the market has not recognized the P1 trial and may be waiting on results for evidence of safety. The potential is here for some nice gains from the right entry point. 

The recent AGM did state that key work is being done to support the P2, which most investors here would take with a grain of salt, given the history, but a quick check at projects ongoing in Finkelstein's Parkinson's lab there revealed three projects ongoing. 

Multiple System Atrophy: a rare Parkinsonsim

This project aims to better understand the biology of MSA

Supervisor: Associate Professor David Finkelstein

Overcoming the sprouting limit of axons in the brain - using biomaterials for the treatment of Parkinson’s disease

Current pharmacological or surgical therapies for Parkinson’s disease (PD) offer only symptomatic relief.

Supervisor: Associate Professor David Finkelstein

Does early life exposure to iron represent a risk for Parkinson’s disease?

Brain iron increases with age; a phenomenon that is further accelerated in Parkinson’s disease.

Supervisor: Associate Professor David Finkelstein

That first MSA project may be part of what Prana spoke about as key work to support the P2. Finkelstein has done a lot of work with PBT434, but there was only mention of drugs, but no specifics about PBT434.

All just my opinion. DYOR